Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;50(11-12):1243-1244.
doi: 10.1111/apt.15537.

Editorial: evolving histological assessment of NASH

Affiliations
Editorial

Editorial: evolving histological assessment of NASH

Ian A Rowe. Aliment Pharmacol Ther. 2019 Dec.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Rinella ME, Tacke F, Sanyal AJ, Anstee QM., participants of the AEW. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424-1436.
    1. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L., American Association for the Study of Liver D, United States F, Drug A. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405.
    1. Cheung A, Neuschwander-Tetri BA, Kleiner DE, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019. https://doi.org/10.1002/hep.30672 [Epub ahead of print.]
    1. Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:1-2.
    1. Pai RK, Kleiner DE, Hart J, et al. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther. 2019;50:1100-1111.

LinkOut - more resources